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It is now well established that cancer is a genetic disease and that somatic mutations of oncogenes and tumour suppressor genes are
the initiators of the carcinogenic process. The phosphatidylinositol 3-kinase signalling pathway has previously been implicated in
tumorigenesis, and evidence over the past year suggests a pivotal role for the phosphatidylinositol 3-kinase catalytic subunit, PIK3CA,
in human cancers. In this review, we analyse recent reports describing PIK3CA mutations in a variety of human malignancies, and
discuss their possible implications for diagnosis and therapy.
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Recently, somatic mutations in many different human cancers
were discovered in the gene encoding for the phosphatidylinositol
3-kinase (PI3K) catalytic subunit, PIK3CA. In this review, we will
be analysing and consolidating these findings, and discuss their
possible implications in cancer progression and therapy. Due to
the focused nature of this review, the PI3K pathway and its
biochemical signalling properties will not be discussed in detail.
The reader is directed toward several excellent recent reviews for a
more comprehensive analysis of this pathway (Hennessy et al,
2005; Wymann and Marone, 2005).
PHOSPHATIDYLINOSITOL 3-KINASE OVERVIEW
The PI3Ks are heterodimeric lipid kinases composed of catalytic
and adaptor/regulatory subunit variants encoded by separate
genes and alternative splicing. Phosphatidylinositol 3-kinases are
important regulators of cellular growth, transformation, adhesion,
apoptosis, survival and motility (Volinia et al, 1994; Fruman et al,
1998; Cantley, 2002). The PI3K family of enzymes are organised
under three main classes (class I, II and III) and various subgroups
have been categorised based on their primary structure, substrate
specificity and regulation (Vivanco and Sawyers, 2002).
Both the catalytic and regulatory subunits of the human PI3K
gene were cloned by Volinia et al (1994) and the overall sequence
was found to be highly homologous to the bovine and yeast PI3K
genes. The activation of PI3K results in the generation of the
second messenger, phosphatidylinositol 3,4,5 trisphosphate (PIP3)
from phosphatidylinositol 4,5 bisphosphate (PIP2) (Figure 1A).
The activation of PI3K by a growth factor bound (activated)
receptor tyrosine kinase (RTK) and subsequent production of PIP3
drives the various downstream pathways that regulate a number of
cellular functions including those involved in tumour development
and progression (Figure 1B).
PHOSPHATIDYLINOSITOL 3-KINASE AND HUMAN
CANCER
The kinase activity of PI3K was first reported to be associated with
viral oncoproteins (Cantley et al, 1991). Subsequent studies
employing mouse knockouts of both the regulatory and catalytic
subunits of PIK3 resulted in a number of deficits including
embryonic lethality, B cell defects, liver necrosis and colorectal
cancer (Katso et al, 2001). Other investigations showed that the
amplification of the PI3K locus as well as deletions of short
nucleotide sequences resulted in elevated lipid kinase activity of
the p110a catalytic subunit of PI3K (PIK3CA) in various cancer
types with the implication that PI3K was functioning as an
oncogene (Volinia et al, 1994; Shayesteh et al, 1999; Ma et al, 2000;
Katso et al, 2001; Migozuchi et al, 2004; Pedrero et al, 2005). The
PIK3CA p110a catalytic subunit of PI3K will be highlighted in this
review due to the recent alterations of this protein found in
primary human cancers. PIK3CA is a 34kb gene located on
chromosome 3q26.3 that consists of 20 exons coding for 1068
amino acids yielding a 124kDa size protein (Figure 1C). Gene
amplifications, deletions and more recently, somatic missense
mutations in the PIK3CA gene have been reported in many human
cancer types including cancers of the colon, breast, brain, liver,
stomach and lung. These somatic missense mutations were
proposed to increase the kinase activity of PIK3CA contributing
to cellular transformation. The first of these mutational reports
was published by Samuels et al (2004). In this seminal paper, the
authors initially analysed the sequence of eight PI3K and eight
PI3K-like genes in a relatively small number of primary colorectal
tumours and discovered that PIK3CA was the only gene
harbouring somatic mutations. They subsequently expanded their
sample size, which included tissues from primary tumours of the
colon, brain, breast, stomach and lung. Their results verified their
initial observations and demonstrated that somatic mutations were
found in all of these tissues at varying frequencies. Notably,
colorectal, brain and gastric cancers were found to have a high rate
of PIK3CA gene mutation with frequencies of 32, 27 and 25%,
respectively. Breast and lung cancers had a relatively low rate of
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www.bjcancer.comPIK3CA mutations (8 and 4% respectively), although the sample
size of all cancer types was relatively small (n¼12–24) with the
exception of colorectal cancers (n¼234). These somatic missense
mutations were scattered across most of the exons, but were
predominantly found in the kinase and helical domains of the
PIK3CA subunit (Table 1). Of note, ‘hotspot’ or frequently
recurring mutations were found in exon 9 (G1624A:E542K) and
exon 20 (A3140G:H1047R) in this analysis. Based on all sequencing
data (Table 1), there now appear to be three hotspots mutations
within PIK3CA: H1047R, E542K and E545K. Bachman et al (2004)
expanded this report using a larger sample set consisting of
primary breast cancers and breast cancer cell lines. Their data
demonstrated that on average 25% of breast cancers harbour
missense mutations in either the kinase, helical or p85 binding
domains, although it should be noted that only the three exons
corresponding to these domains were sequenced in their analysis.
Many other studies followed, examining PIK3CA mutations in
various cancer types (Table 1). Campbell et al (2004) sequenced all
of the 20 coding exons of PIK3CA from primary tumour samples of
breast, ovarian and colorectal cancers and reported new mutations
found in exons 6, 7 and 9, as well as mutations previously reported
by others. They reported a PIK3CA mutation frequency of 18.8% in
colorectal cancers and among 70 breast cancer samples, they noted
a mutation frequency of 40%, which is thus far the highest
reported in any cancer type (Table 1). The frequency of ovarian
cancers was reported as 6%, but of note, mutations clustered
according to the histologic subtype with endometrioid and clear
cell variants having a much higher rate than serous and mucinous
ovarian cancers. In both the studies by Bachman et al and
Campbell et al, no association was noted between the presence of
PIK3CA mutations with other prognostic/clinical features of breast
cancer, including histologic subtype, oestrogen/progesterone
receptor expression, Her2/neu receptor status, axillary lymph
node positivity, grade and/or stage of the tumour. This is in
contrast to a more recent analysis by Saal et al (2005) where these
authors examined a total of 292 primary breast cancers and found
an overall mutation rate of 26%. In this study, the authors
described a statistically significant correlation between the
presence of PIK3CA mutations and the presence of nodal
metastases, oestrogen/progesterone receptor positivity and Her2/
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Figure 1 (A) The main reaction catalysed by PI3K: phosphatidylinositol (PI) 4,5 bisphosphate (PIP2) to phosphatidylinositol (PI) 3,4,5-triphosphate (PIP3).
(B) PI3K is activated upon ligand binding to a receptor tyrosine kinase (RTK), which then activates the regulatory subunit (p85) to bind the catalytic p110a
subunit. This ultimately triggers various downstream signalling cascades resulting in cell survival, apoptosis, transformation, metastasis, and cell migration. (C)
Schematic representation of PIK3CA (p110a catalytic subunit of PI3K) and its functional domains with the most common somatic mutations, E542K, E545K
and H1047R within the helical and kinase domains indicated.
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strated a statistically significant correlation between the presence
of PIK3CA mutations and the presence of PTEN expression, an
intriguing finding given the known roles of these two pathways
and similar findings in brain cancers (see below). As described by
Saal et al, variations in sample size likely account for the
discrepancies between their study and those of Bachman et al
and Campbell et al, although regional bias in the tumour samples
is still a possibility given that roughly half their samples were from
a Swedish cohort that included almost exclusively Stage II breast
cancers. Additionally, Levine et al (2005) sequenced PIK3CA exons
9 and 20 in 198 ovarian and 72 breast cancers using primary tissue
samples and found an overall mutation rate of 12% for ovarian
cancers and 18% for breast cancers, although no correlation with
histologic subtypes and/or clinical/prognostic indicators were
found for either type of cancer. Finally, Broderick et al (2004)
sequenced the PIK3CA gene in 285 brain tumours and found a
mutational rate of 5%, which was significantly lower than the rate
originally reported by Samuels et al (2005). While the majority of
their mutations were in known hotspot regions of the gene, these
authors also found that PIK3CA mutations were restricted to
certain histologic subtypes. They also showed in a limited analysis
that PIK3CA mutations were mutually exclusive with mutations of
the tumour suppressor PTEN, suggesting that tumorigenic
signalling through this pathway can occur either through
activation of PIK3CA or inactivation of PTEN. Given the
Table 1 Somatic mutations of PIK3CA in cancer types reported since 10/2005
Cancer % PIK3CA mutation
a
Sample source
(primary tissue
vs cancer cell line) Exon mutated Functional domain Reference
Liver 35.6 (26/73) Primary 9 and 20 Helical and kinase Lee et al (2004)
Total liver 36% (26/73)
Breast 33.3 (4/12) Cell lines 9 and 20 Helical and kinase Bachman et al (2004)
Breast 21.4 (9/42) Primary 1, 9 and 20 p85, helical and kinase Bachman et al (2004)
Breast 18.1 (13/72) Primary 9 and 20 Helical and kinase Levine et al (2005)
Breast 40.0 (28/70) Primary 6, 7, 9 and 20 C2, helical and kinase Campbell et al (2004)
Breast 20.7 (19/92) Primary 9 and 20 Helical and kinase Wu et al (2005a)
Breast 8.3 (1/12) Primary 20 kinase Samuels et al (2004)
Breast 33.3 (5/15) Cell lines 9 and 20 Helical and kinase Wu et al (2005a)
Breast 26.9 (25/93) Primary 9 and 20 Helical and kinase Lee et al (2004)
Breast 28.0 (14/50) Cell lines 1, 9 and 20 p85, helical and kinase Saal et al (2005)
Breast 26.4 (77/292) Primary 1, 4, 7, 9, 13, 18, 20 p85, C2, helical and kinase Saal et al (2005)
Total breast 26% (195/750)
Colon 31.6 (74/234) Primary 1, 2, 4, 7, 9, 18 and 20 P85, C2, helical and Kinase Samuels et al (2004)
Colon 13.6 (14/103) Primary 9 and 20 Helical and kinase Velho et al (2005)
Colon 18.8 (6/32) Primary 9 and 20 Helical and kinase Campbell et al (2004)
Total colon 25% (94/369)
Ovarian 12.1 (24/198) Primary 9 and 20 Helical and kinase Levine et al (2005)
Ovarian 6.0 (11/182) Primary 9 and 20 Helical and kinase Campbell et al (2004)
Total ovarian 9% (35/380)
Gastric 25.0 (3/12) Primary 18 and 20 Kinase Samuels et al (2004)
Gastric 10.6 (5/47) Primary 9 and 20 Helical and kinase Velho et al (2005)
Gastric 6.5 (12/185) Primary 9 and 20 Helical and kinase Lee et al (2004)
Gastric 4.3 (4/94) Primary 9 and 20 Helical and kinase Li et al (2005)
Total gastric 7% (24/338)
Brain 26.7 (4/15) Primary 4, 5 and 13 C2 and helical Samuels et al (2004)
Brain 4.6 (13/285) Primary 9 and 20 Helical and kinase Broderick et al (2004)
Total brain 6% (17/300)
Lung 1.3 (3/229) Primary 9 and 20 Helical and kinase Lee et al (2004)
Lung 4.2 (1/24) Primary 9 Helical Samuels et al (2004)
Total lung 2% (4/253)
Leukaemia 1.1 (1/88) Primary 9 Helical Lee et al (2004)
Total leukaemia 1% (1/88)
Total cancers reported 15% (382/2551)
aThe majority of PIK3CA documented mutations being somatic missense mutations, this table does not include other genetic changes (i.e. gene amplifications, deletions, insertions,
etc.).
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conflicting results of the above studies, the association of PIK3CA
mutations with other clinical and histologic parameters is still not
definitively known.
Another recent study (Lee et al, 2004) demonstrated a very high
rate (36%) of PIK3CA somatic mutations in liver cancer. In the
same study, these authors also analysed tissues from breast, gastric
and lung cancers using a relatively high sample size and found
mutation rates similar to other studies (Table 1). Interestingly, the
authors also found one PIK3CA mutation out of 88 acute
leukaemias (mutation rate¼1.1%) that were analysed in this
study, suggesting that PIK3CA mutations are not limited to solid
tumours of epithelial origin. An analysis of PIK3CA somatic
mutations and amplifications in thyroid cancers (Wu et al, 2005b)
did not reveal any PIK3CA mutations; however, this group did find
PIK3CA gene amplification in 12% of thyroid adenomas, 5% of
papillary thyroid cancers, 24% of follicular thyroid cancers and
71% of thyroid cancer cell lines. More recently, there has been a
report of somatic mutations in genes (i.e. PDK1, AKT2 and PAK4)
downstream of the PI3K signalling pathway (Parsons et al, 2005).
Although the frequency of mutations and the discovery of
hotspot heterozygous mutations strongly argue for the importance
of PIK3CA in the carcinogenic process, functional analysis of these
mutations has also been performed to confirm this supposition.
Overexpression of common hotspot PIK3CA mutations, as well as
gene deletion experiments using somatic cell knockouts, has
demonstrated that these mutations are in fact oncogenic (Ikenoue
et al, 2005; Kang et al, 2005; Samuels et al, 2005). Kang et al (2005)
overexpressed cDNAs containing the common PIK3CA mutations,
E542K, E545K, and H1047R, in chicken embryo fibroblasts. Their
study demonstrated that overexpression of these mutant PIK3CA
proteins led to cellular transformation with concomitant phos-
phorylation of proteins in the AKT pathway. Through the use of
somatic cell knockouts, Samuels et al (2005) reported that
mutation of the PIK3CA kinase domain in the HCT116 colon
cancer cell line, and mutation of the helical domain in the DLD1
colon cancer cell line, resulted in increased activity of the PIK3CA
enzyme as manifested by increased cell signalling, cell growth and
invasion. Another functional study examining the E542K, E545K
and H1047R hotspots was reported by Ikenoue et al (2005). These
authors found that an increase in PIK3CA kinase activity and
cellular transformation occurred when the above-mentioned
mutant PIK3CA sequences were introduced into mouse NIH 3T3
cells.
By combining the copious amount of sequencing data over the
past year, we find that the PIK3CA gene is mutated on average in
15% of human cancers, although there is obviously great
variability in the tissue type, that is, colon vs breast vs lung
(Table 1). In most tissue types, mutations predominantly cluster
within the three aforementioned hotspots: E542K, E545K and
H1047R (Figure 1C). It is now evident that cancers of the liver,
colon and breast harbour the most PIK3CA mutations with average
mutational frequencies (across the reported studies) of 36, 26 and
25%, respectively (Table 1). The mutational studies that are
summarised in Table 1 do reveal some conflicting results, however,
and as previously mentioned these are likely due to a number of
factors including geographical variation/influence, sample source
preservation and methods used for DNA isolation. However,
despite these discrepancies, the high frequency of PIK3CA
mutation and the discovery of hotspot mutations have important
clinical implications for diagnosis, prognosis and therapy. For
example, using PCR and sequencing of hotspot mutations,
increased diagnostic sensitivity of cancer may be possible in
situations of histologic ambiguity. As a case in point, detection of
disease positive nodes in breast cancer may benefit from this
type of molecular diagnostic test. The detection and prognostic
significance of micrometastatic nodal disease in breast cancer
has yielded conflicting and controversial results, and so far,
no definitive data have been presented (Sakorafas et al, 2004;
Colleoni et al, 2005; Kuijt et al, 2005). This may be due in
part to the lack of specificity used in these studies to detect
cancerous cells within normal appearing lymph nodes. One
could envision that if a woman’s primary breast cancer
harboured a PIK3CA mutation, then that same mutation could
be screened for in her axillary lymph nodes that were otherwise
histologically normal, using recently developed technologies that
allow for the detection of minute amounts of mutant DNA
molecules (Dressman et al, 2003; Diehl et al, 2005). From a
prognostic standpoint, long-term prospective, blinded randomised
trials could be performed to determine if the presence or absence
of PIK3CA mutations have any correlation with clinical outcome in
various cancer types. This would then allow for the clinician to
predict with a fair amount of certainty whether or not cancers
harbouring these mutations would be more or less aggressive and
could therefore influence decisions regarding additional systemic
therapies. Finally, targeted therapies such as Imatinib mesylate
(anti-BCR/ABL and cKIT), Gefitinib and Erlotinib (anti-EGFR)
that appear to impart a high degree of specificity for translocated/
mutated oncogenes give hope that therapies targeted specifically
against mutant PIK3CA can be developed (Druker et al, 2001;
Lynch et al, 2004; Paez et al, 2004). Given the high degree of
PIK3CA mutations in human cancers, this could have a
tremendous impact on eliminating the morbidity and mortality
of malignant diseases.
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